Clinic
Christus Health Southeast Texas
Christus Health Southeast Texas was paid $21.00M by Medicaid between May 2019 and Dec 2024, across 134 billing codes. Its largest line is 99284, emergency room visit (serious) — 42% of everything it billed.
33Billing provider infoCHRISTUS HEALTH SOUTHEAST TEXAS
BEAUMONT, TX 77702
BEAUMONT, TX 77702
33aNPI1679557888assigned 12/01/2005
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$21.00M
24GClaims270,425
24DCodes billed134
24AFirst – last monthMay 2019 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#22 of 320
Median peer was paid$205K
This provider vs. median102×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official TREVINO, PAUL controls 11+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 106 | $727.92 | |
| 2020 | 10,298 | $879K | |
| 2021 | 62,123 | $3.61M | |
| 2022 | 83,668 | $6.03M | |
| 2023 | 78,745 | $7.28M | |
| 2024incomplete | 35,485 | $3.20M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 42% | 22,094 | 20,903 | $8.88M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 34,176 | 33,114 | $3.78M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.6% | 3,011 | 2,811 | $2.02M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 5.4% | 1,499 | 1,475 | $1.14M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 5.0% | 4,733 | 4,174 | $1.04M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.9% | 7,976 | 7,730 | $819K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.6% | 10,709 | 5,295 | $328K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.4% | 1,002 | 964 | $294K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 20,443 | 18,766 | $206K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,751 | 3,652 | $194K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 7,164 | 6,841 | $194K |
| 80053 | Comprehensive metabolic panel | <1% | 14,193 | 13,135 | $186K |
122 more codes
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,192 | $184K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 5,001 | $149K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,417 | $127K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,399 | $115K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,955 | $84K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,942 | $83K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,182 | $78K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,177 | $74K |
| 87081 | <1% | 5,508 | $66K | |
| 76937 | <1% | 484 | $57K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 103 | $57K |
| 81025 | <1% | 4,412 | $52K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 530 | $38K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 806 | $38K |
| 81003 | <1% | 12,099 | $37K | |
| G0378 | Hospital observation service, per hour | <1% | 34 | $37K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 696 | $36K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 344 | $36K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 921 | $35K |
| 84484 | <1% | 3,581 | $33K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 748 | $29K |
| 83880 | <1% | 1,190 | $25K | |
| 80050 | General health panel | <1% | 53 | $25K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 1,053 | $22K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,674 | $20K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 150 | $19K |
| 36410 | <1% | 198 | $16K | |
| 87420 | <1% | 531 | $15K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,232 | $15K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 146 | $14K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,539 | $14K |
| 86850 | <1% | 373 | $13K | |
| 83690 | <1% | 1,869 | $12K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,561 | $12K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 175 | $10K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,509 | $10K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,914 | $10K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 175 | $9K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 93 | $8K |
| 82077 | <1% | 436 | $8K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,147 | $8K |
| 80061 | Lipid panel | <1% | 600 | $7K |
| 84702 | <1% | 528 | $7K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 69 | $7K |
| 81001 | <1% | 1,795 | $6K | |
| 87077 | <1% | 1,488 | $6K | |
| 73562 | <1% | 187 | $6K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,082 | $6K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 760 | $5K |
| 87186 | <1% | 1,252 | $5K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 212 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 509 | $5K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 142 | $5K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,088 | $5K |
| 80143 | <1% | 152 | $4K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 457 | $4K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 146 | $4K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 233 | $4K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 77 | $4K |
| 83655 | <1% | 163 | $4K | |
| 73030 | <1% | 272 | $4K | |
| 81002 | <1% | 669 | $4K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 16 | $4K |
| 80179 | <1% | 137 | $3K | |
| 80074 | <1% | 37 | $3K | |
| 84439 | <1% | 423 | $3K | |
| 85027 | <1% | 698 | $3K | |
| 85651 | <1% | 364 | $3K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 169 | $3K |
| 36415 | Collection of venous blood by venipuncture | <1% | 29,374 | $3K |
| 85730 | <1% | 1,046 | $3K | |
| 84703 | <1% | 393 | $3K | |
| 20610 | <1% | 514 | $3K | |
| 86703 | <1% | 116 | $3K | |
| 85610 | <1% | 1,292 | $3K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 42 | $2K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,308 | $2K |
| 86901 | <1% | 871 | $2K | |
| 74018 | <1% | 45 | $2K | |
| 86900 | <1% | 872 | $2K | |
| 82550 | <1% | 461 | $2K | |
| 73630 | <1% | 53 | $2K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 224 | $2K |
| 83735 | <1% | 464 | $2K | |
| 80047 | <1% | 166 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 666 | $2K |
| 89220 | <1% | 29 | $1K | |
| 87040 | <1% | 181 | $1K | |
| 73610 | <1% | 58 | $1K | |
| 88312 | <1% | 131 | $1K | |
| 84480 | <1% | 91 | $1K | |
| 73502 | <1% | 28 | $1K | |
| 86328 | <1% | 39 | $970.31 | |
| 74019 | <1% | 17 | $899.89 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 569 | $891.46 |
| 83605 | <1% | 105 | $854.07 | |
| 80055 | <1% | 12 | $776.57 | |
| 85014 | <1% | 154 | $706.17 | |
| 85018 | <1% | 154 | $706.17 | |
| 88313 | <1% | 103 | $605.35 | |
| 88720 | <1% | 57 | $540.27 | |
| 73560 | <1% | 41 | $537.17 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 30 | $488.75 |
| 86592 | <1% | 98 | $395.34 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 52 | $327.27 |
| 83525 | <1% | 13 | $284.77 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 117 | $221.71 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 16 | $213.68 |
| 82951 | <1% | 13 | $175.60 | |
| 83970 | <1% | 13 | $166.78 | |
| 87210 | <1% | 13 | $122.53 | |
| 96376 | <1% | 67 | $102.72 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 36 | $76.85 |
| 84436 | <1% | 12 | $65.88 | |
| 84479 | <1% | 12 | $61.98 | |
| 84550 | <1% | 13 | $60.90 | |
| 80076 | <1% | 16 | $16.49 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 909 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 216 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 172 | $0.00 |
| A9270 | Non-covered item or service | 0% | 1,551 | $0.00 |
| 82962 | 0% | 1,355 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTREVINO, PAUL (CEO)
| Provider | Location | Paid |
|---|---|---|
| Christus Health Southwestern Louisiana | Lake Charles, LA | $11.89M |
| Christus Health Southwestern Louisiana | Lake Charles, LA | $10.18M |
| Christus Health Southeast Texas | Jasper, TX | $5.51M |
| Christus Health Southeast Texas | Jasper, TX | $699K |
| Christus Health Southwestern Louisiana | Lake Charles, LA | $223K |
| Christus Health Southwestern Louisiana | Lake Charles, LA | $145K |
| Christus Health Southwestern Louisiana | Lake Charles, LA | $136K |
| Christus Health Southwestern Louisiana | Grand Chenier, LA | $113K |
| Christus Health Southeast Texas | Kirbyville, TX | $86K |
| Christus Health Southwestern Louisiana | Lake Charles, LA | $41K |
| Christus Health Southeast Texas | Beaumont, TX | $175.14 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.